Jan 28 (Reuters) -
KAINOS LABORATORIES INC
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2009 Dec 31, 2008 Mar 31, 2010
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST Sales 3.12 2.63 4.10
(+18.8 pct) Operating prft 176 mln loss 15 mln prft 190 mln Recurring prft 159 mln loss 31 mln prft 166 mln Net 79 mln 144 mln 85 mln
(-45.2 pct) EPS Y17.80 Y32.46 Y19.08
NOTE - Kainos Laboratories Inc is a manufacturer of clinical reagents for biochemical and immune serum studies.
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half dividend and Q4 to the second-half dividend announced before a new corporate law in 2006 allowed companies to pay and report dividends on a quarterly basis.
For latest earnings estimates made by Toyo Keizai, please double click on 4556.TK1.